A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
<br/><strong>Background: </strong>Cryptococcal meningitis is a leading cause of death in HIV-infected patients. International treatment guidelines recommend induction therapy with amphotericin B and flucytosine. This antifungal combination is most effective, but unfortunately flucy...
主要な著者: | Ngan, N, Mai, N, Tung, N, Lan, N, Tai, L, Phu, N, Chau, N, Binh, T, Hung, L, Beardsley, J, White, N, Lalloo, D, Krysan, D, Hope, W, Geskus, R, Wolbers, M, Nhat, L, Thwaites, G, Kestelyn, E, Day, J |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Wellcome Trust
2019
|
類似資料
-
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
著者:: Ngan, NTT, 等
出版事項: (2021) -
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
著者:: Nguyen Thi Thuy Ngan, 等
出版事項: (2021-09-01) -
A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. [version 1; referees: 2 approved]
著者:: Nguyen Thi Thuy Ngan, 等
出版事項: (2019-01-01) -
Statistical Analysis Code: AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL OF TAMOXIFEN COMBINED WITH AMPHOTERICIN B AND FLUCONAZOLE FOR CRYPTOCOCCAL MENINGITIS
著者:: Ngan, N, 等
出版事項: (2021) -
The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans
著者:: Hai, T, 等
出版事項: (2019)